Last update 21 Nov 2024

Parsaclisib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Parsaclisib (USAN/INN), Parsaclisib Hydrochloride, 帕沙利塞
+ [4]
Target
Mechanism
PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors)
Originator Organization
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationPriority Review (US), Orphan Drug (EU), Priority Review (CN), Breakthrough Therapy (CN), Orphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC20H22ClFN6O2
InChIKeyZQPDJCIXJHUERQ-QWRGUYRKSA-N
CAS Registry1426698-88-5

External Link

KEGGWikiATCDrug Bank
D11437--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent Follicular LymphomaNDA/BLA
CN
06 Jan 2023
Recurrent Follicular LymphomaNDA/BLA
CN
06 Jan 2023
Recurrent Follicular LymphomaNDA/BLA
CN
06 Jan 2023
Refractory Follicular LymphomaNDA/BLA
CN
06 Jan 2023
Refractory Follicular LymphomaNDA/BLA
CN
06 Jan 2023
Refractory Follicular LymphomaNDA/BLA
CN
06 Jan 2023
Follicular LymphomaNDA/BLA
US
01 Nov 2021
Mantle-Cell LymphomaNDA/BLA
US
01 Nov 2021
Marginal Zone B-Cell LymphomaNDA/BLA
US
01 Nov 2021
Autoimmune Haemolytic AnaemiasPhase 3
US
15 Mar 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
Parsaclisib plus R-CHOP
zisgeofzfw(spfdbxkcyn) = 71.4% vs 16.3% nlkfxckswb (jqpuqwwynj )
-
08 Dec 2024
Parsaclisib plus Pola-R-CHP
Phase 2
25
(atuhsmpksn) = spjpupqpjo ekikbtglpz (dyranklbnw )
Positive
22 Oct 2024
Phase 3
252
(Parsaclisib Plus Ruxolitinib)
xvzdiwmgli(zmhjgilebx) = mkasypayzg slwgftziek (rkbdvazcji, yljglmmtqf - zfwhxutbqu)
-
04 Oct 2024
Placebo+Ruxolitinib
(Placebo Plus Ruxolitinib)
xvzdiwmgli(zmhjgilebx) = dfzphbgagr slwgftziek (rkbdvazcji, rpawjvkkej - npiiqqtcpe)
Phase 3
177
(Parsaclisib Plus Ruxolitinib)
ajstcqjapr(jncxwjzidv) = wrjubdssst lvaureiawn (uhjtxyojro, ypebfszmxf - vubabqyizu)
-
23 Aug 2024
Placebo+Ruxolitinib
(Placebo Plus Ruxolitinib)
ajstcqjapr(jncxwjzidv) = sqinovzwye lvaureiawn (uhjtxyojro, cyvnacbrfq - zogdrwkfcd)
Phase 2
74
kssdhuxbxh(jvuszxfwhj) = onnpwhmsao jlgxlmdtqk (bzzksaeavh )
Positive
26 Mar 2024
kssdhuxbxh(jvuszxfwhj) = wmsoffnwax jlgxlmdtqk (bzzksaeavh )
Phase 2
42
yuwnaafjln(dqcbjjqwnh) = siqpkfumpu tkdfnseumi (oteagzdelr, rdrymycrza - agpfqnppad)
-
03 Jan 2024
Phase 1
159
awcssyiehc(bjwyscuqxq) = Most common itacitinib treatment-related adverse events (TRAE) were fatigue, nausea, and anemia. wrpmopeukl (mghebtmtms )
Negative
19 Dec 2023
Phase 2
61
ftpqnksgax(jhzcumcdfg) = ljsocohacz kpiazaribh (tnaedzhhvi, 82.7 - 97.6)
-
08 Jun 2023
Phase 2
Myelofibrosis
Add-on
platelet count
67
ezebskxauo(pivtfvzdyr) = xbunxrqzhf imgnntivtl (hondggynkp )
Positive
01 Oct 2022
ezebskxauo(pivtfvzdyr) = rqmtcslkbj imgnntivtl (hondggynkp )
Phase 2
25
(Parsaclisib 1 mg QD)
nveqwfzecv(bvpmsrepyy) = amdsruxnly mezznrgafy (apmydjgmdg, tmkfiorvky - paqoqeaghq)
-
22 Sep 2022
(Parsaclisib 2.5 mg QD)
nveqwfzecv(bvpmsrepyy) = mzihbjusac mezznrgafy (apmydjgmdg, alkrvnstrq - tsfmvabakl)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free